Full-Time

Human Resources Service Centre Manager

CSL

CSL

10,001+ employees

Develops and delivers biotherapies and vaccines

No salary listed

Liverpool, UK

In Person

Bachelor's

Category
People & HR (1)
Required Skills
ServiceNow
Workday HRIS
Quality Assurance (QA)

Get referred to CSL

See people who can refer or advise you

Requirements
  • A Bachelor's degree in Human Resources Management or a related field, CIPD Level 5, or equivalent is required.
  • Proven experience managing a multi-country Human Resources Service Center supporting the EMEA region is required.
  • Demonstrable people leadership experience, including performance management and team development, is required.
  • Experience owning and delivering Human Resources Service Center improvement projects end-to-end is required.
  • A track record of driving performance against defined service-level agreement and quality targets is required.
  • Working knowledge of EMEA employment law and Human Resources compliance across multiple jurisdictions is required.
  • Hands-on experience with Workday and/or ServiceNow, or comparable platforms, is required.
Responsibilities
  • Lead, coach, and develop a team of five HR Operations Advisers by holding regular one-to-one meetings, identifying capability gaps, creating individual development plans, and building a high-performing, engaged team.
  • Own and drive Human Resources Service Center performance against defined service-level agreements.
  • Maintain and continuously improve quality standards across transaction accuracy, customer service behaviours, and audit outcomes.
  • Drive and lead Human Resources Service Center process improvement initiatives across the EMEA region by identifying inefficiencies, designing better ways of working, and building the operational infrastructure of the function alongside day-to-day delivery.
  • Ensure all HR processes, transactions, and advice delivered by the team comply with relevant EMEA employment legislation and company policy, while maintaining up-to-date knowledge across the region.
  • Collaborate with HR Operations Specialists, Global and Regional HR Service Center leaders, HR Business Partners, Centers of Excellence, Talent Acquisition, HR Technology, and Total Rewards to ensure seamless end-to-end process execution and strong cross-functional relationships.
  • Own and deliver Human Resources Service Center improvement projects end-to-end by leading workstreams, managing timelines, coordinating with relevant stakeholders, and ensuring outputs are implemented in the function.
  • Contribute to the development of knowledge assets, standard operating procedures, and training materials with HR Operations Specialists so the team operates from a consistent, high-quality knowledge base.
  • Act as an escalation point for complex or sensitive cases within the team's remit, resolving issues collaboratively and ensuring future escalations are mitigated and lessons are learned.
  • Monitor and report on team and function performance, providing the Associate Director with timely, accurate data on service-level agreements, quality, customer satisfaction, and team development progress, and using insight to inform priorities and decisions.
Desired Qualifications
  • CIPD Level 7 is desirable.
  • Experience with inContact or similar contact centre telephony is desirable.

CSL is a global biotechnology company that develops and delivers biotherapies and influenza vaccines. It focuses on plasma-derived and recombinant therapies for rare and serious diseases and sells to healthcare providers, hospitals, and governments across the Americas, Asia Pacific, and Europe. Its product range includes treatments for rare diseases, influenza vaccines, and antivenoms, produced through its R&D, manufacturing, and distribution operations. CSL differentiates itself by offering the broadest portfolio of plasma-derived and recombinant therapies and by leveraging its global footprint and emphasis on diversity to reach diverse markets. The company’s main goal is to save lives and protect health by expanding access to high-quality therapies and vaccines worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Parkville, Australia

Founded

1916

Get referred to CSL

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FY26 HEMGENIX sales rose 25%, validating CSL’s gene-therapy commercialization engine.
  • CSL completed $176 million in FY26 cost savings, ahead of plan.
  • VarmX’s September 2025 option deal adds a potential $2.1 billion anticoagulation franchise.

What critics are saying

  • FY26 revenue fell 1% and underlying NPATA fell 2% on plasma weakness.
  • China albumin sales dropped 17% in FY26 after government cost-containment measures.
  • Pentagon ended the U.S. flu vaccine mandate in 2026, pressuring Seqirus demand and execution.

What makes CSL unique

  • CSL spans plasma, gene therapy, and influenza vaccines, unlike single-platform biotech peers.
  • HEMGENIX remains the only approved hemophilia B gene therapy across the U.S. and Europe.
  • CSL’s global plasma collection and manufacturing network supports hard-to-replicate immunoglobulin and albumin supply.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

2%
Yahoo Finance
Aug 17th, 2026
CSL reports 2% drop in annual profit to $3.14B on weak plasma sales

Australian biopharmaceutical company CSL reported a 2% decline in annual profit on Tuesday, as its core plasma division experienced falling revenue. The company posted an underlying net profit after tax of $3.14 billion on a constant currency basis for the year ended 30 June, down from $3.22 billion the previous year. CSL is among the world's leading flu vaccine manufacturers. The results reflect challenges in the plasma business, which forms a significant part of the company's operations.

Yahoo Finance
May 2nd, 2026
CSL to split Seqirus vaccine unit as shares slide 50% amid restructure and cost cuts

CSL has announced a restructuring plan including the separation of its Seqirus influenza vaccine business into a standalone entity, alongside workforce reductions and plasma collection centre closures. Management cited prolonged margin pressures and operational challenges as drivers for the changes. The announcement follows a sharp share price decline, with CSL trading at A$124.84, down 27.4% year-to-date and 50.1% over the past year. Three-year and five-year returns show declines of 56.3% and 51.0% respectively. The restructuring aims to simplify operations and refocus capital on higher-returning areas. Separating Seqirus could provide clearer visibility into CSL's core plasma and specialty therapies businesses, whilst allowing independent capital allocation decisions. However, investors face execution risks typical of separations of this scale, including one-off charges and operational disruption.

Yahoo Finance
Apr 23rd, 2026
CSL shares hit 2017 low as Pentagon scraps flu vaccine mandate for military personnel

Australian biotech CSL extended losses on Thursday, falling to its lowest level since August 2017, after the US Pentagon scrapped its flu vaccine mandate for military personnel. The stock dropped as much as 0.8%, bringing yearly losses to over 25%. The policy reversal threatens demand from a key institutional buyer, compounding CSL's existing challenges. The company's Seqirus vaccines unit generated $2.17 billion in revenue in fiscal 2025, representing 14% of total revenue. CSL has faced sustained pressure from slowing demand for plasma-derived therapies, higher costs and multiple earnings downgrades. The stock plunged 39% last year, its biggest annual drop since 2002. Analysts cite concerns over falling US flu vaccination rates, weaker Seqirus earnings and delayed strategic plans.

USA Herald
Sep 16th, 2025
CSL to Acquire VarmX in $2.2B Biotech Breakthrough Deal - USA Herald

In a high-stakes move that could reshape emergency medicine, global biotech giant CSL has struck an exclusive option agreement to acquire VarmX, a Netherlands-based biotech, in a deal valued at up to $2.2 billion. The announcement, made Tuesday by EQT Life Sciences, which counts VarmX in its portfolio, underscores just how valuable the Dutch company’s CSL to acquire VarmX in a $2.2B deal, backing breakthrough bleeding drug VMX-C001 with full trial funding.

CSL
Sep 16th, 2025
CSL Limited Celebrates 25 Years on the ASX

Global biotechnology leader, CSL, celebrated the Company’s 25th Anniversary of listing on the Australian Securities Exchange (ASX), commemorating the occasion with a ceremonial bell ring at...